1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 308 Results
Page 3 of 31

Onxeo appoints Julien Miara as new interim CEO


Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

01/03/2022


New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments


These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions   Paris (France), December 8, 2021 […]

12/08/2021


Onxeo Continues to Strengthen its Board of Directors


Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member   Paris […]

11/23/2021


Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector


Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]

10/14/2021


Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities


Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

07/29/2021


Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board


Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee   […]

Tags:


Onxeo: Report on the Combined General Meeting of June 10, 2021


All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]

06/10/2021


Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States


This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]

06/09/2021


Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts


This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]

05/31/2021


Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information


Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

05/21/2021


Page 3 of 31